WO2004013100A3 - N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy - Google Patents

N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy Download PDF

Info

Publication number
WO2004013100A3
WO2004013100A3 PCT/FR2003/002355 FR0302355W WO2004013100A3 WO 2004013100 A3 WO2004013100 A3 WO 2004013100A3 FR 0302355 W FR0302355 W FR 0302355W WO 2004013100 A3 WO2004013100 A3 WO 2004013100A3
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
phenyl
optionally substituted
piperidin
Prior art date
Application number
PCT/FR2003/002355
Other languages
French (fr)
Other versions
WO2004013100A2 (en
Inventor
Emmanuelle Dachary
Gihad Dargazanli
Genevieve Estenne-Bouhtou
Benoit Marabout
Nathalie Rakotoarisoa
Pierre Roger
Mireille Sevrin
Original Assignee
Sanofi Synthelabo
Emmanuelle Dachary
Gihad Dargazanli
Genevieve Estenne-Bouhtou
Benoit Marabout
Nathalie Rakotoarisoa
Pierre Roger
Mireille Sevrin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo, Emmanuelle Dachary, Gihad Dargazanli, Genevieve Estenne-Bouhtou, Benoit Marabout, Nathalie Rakotoarisoa, Pierre Roger, Mireille Sevrin filed Critical Sanofi Synthelabo
Priority to AU2003273474A priority Critical patent/AU2003273474A1/en
Publication of WO2004013100A2 publication Critical patent/WO2004013100A2/en
Publication of WO2004013100A3 publication Critical patent/WO2004013100A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

Disclosed are compounds of general formula (I) in which R1 represents H or an alkyl, cycloalkyl alkyl, phenylalkyl, alkenyl, or alkynyl, X represents H or one or several halogen atoms, alkyl, or alkoxy, R2 represents H or one or several halogen atoms or alkoxy groups, or optionally substituted amino, R3 represents an optionally substituted aminosulfonyl group, a cyano group or a group of formula S-alkyl, an alkylsulfonyl group, a carboxy or alkoxycarbonyl group, an optionally substituted carbamoyl group, an acetyl or benzoyl group, or an alkyl, cycloalkyl, alkenyl, phenyl, thienyl or thianthrenyl group. Said compounds are used for therapeutic purposes.
PCT/FR2003/002355 2002-07-29 2003-07-25 N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy WO2004013100A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003273474A AU2003273474A1 (en) 2002-07-29 2003-07-25 Less thanigreater thannless than/igreater than-(phenyl(piperidin-2-yl)methyl)benzamide derivatives, preparation thereof, and use thereof in therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0209589A FR2842805A1 (en) 2002-07-29 2002-07-29 N- [PHENYL (PIPERIDIN-2-YL) METHYL] BENZAMIDE DERIVATIVES, THEIR PREPARATION AND APPLICATION THERAPEUTICS
FR02/09589 2002-07-29

Publications (2)

Publication Number Publication Date
WO2004013100A2 WO2004013100A2 (en) 2004-02-12
WO2004013100A3 true WO2004013100A3 (en) 2004-04-15

Family

ID=30011557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/002355 WO2004013100A2 (en) 2002-07-29 2003-07-25 N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy

Country Status (3)

Country Link
AU (1) AU2003273474A1 (en)
FR (1) FR2842805A1 (en)
WO (1) WO2004013100A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227930B2 (en) 2010-08-13 2016-01-05 Abbvie Inc. Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9238619B2 (en) 2010-08-13 2016-01-19 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586942B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586945B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408774D0 (en) * 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds
NZ556467A (en) * 2005-01-14 2009-09-25 Organon Nv Glycine reuptake inhibitors for treating drug and alcohol dependence
EP1899294B1 (en) 2005-06-13 2015-03-18 Merck Sharp & Dohme Limited Therapeutic agents
WO2009024611A2 (en) 2007-08-22 2009-02-26 Abbott Gmbh & Co. Kg 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
US8653100B2 (en) 2008-04-01 2014-02-18 Abbvie Inc. Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
AR075182A1 (en) * 2009-01-28 2011-03-16 Astrazeneca Ab 2-AZA-BICYCLE COMPOUNDS (2.2.2) OCTANO AND ITS USES
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (en) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES IN THERAPY
FR2943056A1 (en) * 2009-03-16 2010-09-17 Sanofi Aventis New N-(2-aza-bicyclo(2.2.1)-hex-1-yl)-aryl-methyl-heterobenzamide derivatives are glycine transporter 1 inhibitors useful to treat e.g. dementia, psychosis, schizophrenia, anxiety, panic attacks, and obsessive compulsive disorder
MX2011009677A (en) * 2009-03-16 2011-09-30 Sanofi Sa Derivatives of n-[(2-aza-bicyclo[2.1.1]hex-1-yl)-aryl-methyl]-het erobenzamide, preparation thereof and application of same in therapeutics.
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2013015274A (en) 2011-06-24 2014-03-31 Amgen Inc Trpm8 antagonists and their use in treatments.
JP2014517074A (en) 2011-06-24 2014-07-17 アムジエン・インコーポレーテツド TRPM8 antagonists and their use in therapy
WO2013020930A1 (en) 2011-08-05 2013-02-14 Abbott Gmbh & Co. Kg Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2853254A1 (en) 2011-11-18 2013-05-23 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254569A (en) * 1991-01-14 1993-10-19 The Du Pont Merck Pharmaceutical Company (Amidomethyl)nitrogen heterocyclic analgesics
WO1999045011A1 (en) * 1998-03-06 1999-09-10 Janssen Pharmaceutica N.V. Glycine transport inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254569A (en) * 1991-01-14 1993-10-19 The Du Pont Merck Pharmaceutical Company (Amidomethyl)nitrogen heterocyclic analgesics
WO1999045011A1 (en) * 1998-03-06 1999-09-10 Janssen Pharmaceutica N.V. Glycine transport inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
O. FRIELICH ET AL.: "Asymmetric synthesis. 39. Synthesis of 2-(1-aminoalkyl)piperidines via 2-cyano-6-phenyl oxazolopiperidine", J. ORG. CHEM., vol. 61, 1996, pages 6700 - 6705, XP002235079 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227930B2 (en) 2010-08-13 2016-01-05 Abbvie Inc. Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9238619B2 (en) 2010-08-13 2016-01-19 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586942B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586945B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy

Also Published As

Publication number Publication date
AU2003273474A8 (en) 2004-02-23
AU2003273474A1 (en) 2004-02-23
FR2842805A1 (en) 2004-01-30
WO2004013100A2 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
WO2004013100A3 (en) N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy
WO2004013101A3 (en) N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy
RS20060317A (en) Derivatives of n-/phenyl(alkylpiperidine-2-yl)methyl/ benzamide, preparation method thereof and application of same in therapeutics
WO2005037781A3 (en) Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
NO20062032L (en) Derivatives of N- [phenyl (pyrrolidin-2-yl) methyl] benzamide and N - [(azepan-2-yl) phenylmethyl] benzamide, process for the preparation thereof and use in therapeutic agents
NO20021328L (en) Pyrazolopyrimidia as therapeutic agents
NO20060147L (en) Benzimidazole derivatives, compositions containing them, their preparation and their use
GEP20074033B (en) Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
MA27192A1 (en) N- (PHENYL (PIPERIDIN-2-YL) METHYL) BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
EP1642880A4 (en) Hsp90 family protein inhibitors
NO20064077L (en) Kemokinreseptorantagonister
WO2004031401A3 (en) Novel tyrosine kinases inhibitors
IL180147A0 (en) N - (1 - (1 - benzyl - 4 - phenyl - 1h-imidazol - 2 - yl) - 2,2 - dymethylpropyl) benzamide derivatives and related compounds as kinesin spidle protein (ksp) inhibitors for the treatment of cancer
ATE394383T1 (en) BIPHENYL CARBONIC ACID AMIDE DERIVATIVES AS P38 KINASE INHIBITORS
NO20060146L (en) Benzimidazole derivatives, compositions containing them, their preparation and their use
EP1619180A4 (en) CaSR ANTAGONIST
NO20040881L (en) Oral antidiabetic agents.
AU2003250471A1 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
SE0203303D0 (en) Novel Compounds
AR046131A1 (en) CRYSTAL FORMS OF {2- [1- (3,5- BISTRIFLUORUROMETILBENCIL) -5- PIRIDIN-4-IL-1H- [1,2,3] TRIAZOL- 4-IL] PIRIDIN- 3-IL} - (2- CHLOROPHENYL) METANONE
GB0308201D0 (en) Novel compounds
EE200100646A (en) An almost crystalline form of melagatran
CO5170535A1 (en) DERIVATIVES OF N- [2- (4-AMINOPHENYL) ETHYL] 2,3-DIHIDRO-1,4- BENZODIOXIN-2-METHANAMINE, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
SE0302571D0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
HK1086835A1 (en) N-[({'4-substituted piperazine-1-y}sulfonylmethyl)alkyl]-n-hxdroxyformamide compounds as metallopro teinase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP